RRML - Management of a case of Castleman's disease coexisting with or occurring after transplanted Hodgkin’s lymphoma

Main page
News
RJLabM Credits
Archive
- Current issue
- Ahead of print
- List of published issues
- 2024
  - Nr.1/2024
- 2023
  - Nr.4/2023
  - Nr.3/2023
  - Nr.2/2023
  - Nr.1/2023
  - Supplement 1/2023
- 2022
  - Nr.4/2022
  - Nr.3/2022
  - Nr.2/2022
  - Nr.1/2022
  - Supplement 1/2022
- 2021
  - Nr.4/2021
  - Nr.3/2021
  - Nr.2/2021
  - Nr.1/2021
- 2020
  - Nr.4/2020
  - Nr.3/2020
  - Nr.2/2020
  - Nr.1/2020
  - Supplement 1/2020
- 2019
  - Nr.4/2019
  - Nr.3/2019
  - Nr.2/2019
  - Nr.1/2019
  - Supplement 1/2019
- 2018
  - Nr.4/2018
  - Nr.3/2018
  - Nr.2/2018
  - Nr.1/2018
  - Supplement 1/2018
  - Supplement 2/2018
  - Supplement 3/2018
- 2017
  - Nr.4/2017
  - Nr.3/2017
  - Nr.2/2017
  - Nr.1/2017
  - Supplement 1/2017
- 2016
  - Nr.4/2016
  - Nr.3/2016
  - Nr.2/2016
  - Nr.1/2016
  - Supplement 1/2016
- 2015
  - Nr.4/2015
  - Nr.3/2015
  - Nr.2/2015
  - Nr.1/2015
  - Supplement 1/2015
- 2014
  - Nr.4/2014
  - Nr.3/2014
  - Nr.2/2014
  - Nr.1/2014
  - Supplement 1/2014
- 2013
  - Nr.4/2013
  - Nr.3/2013
  - Nr.2/2013
  - Nr.1/2013
  - Supplement 1/2013
- 2012
  - Nr.4/2012
  - Nr.3/2012
  - Nr.2/2012
  - Nr.1/2012
  - Supplement 1/2012
- 2011
  - Nr.4/2011
  - Nr.3/2011
  - Nr.2/2011
  - Nr.1/2011
  - Supplement 1/2011
- 2010
  - Nr.4/2010
  - Nr.3/2010
  - Nr.2/2010
  - Nr.1/2010
  - Supplement 1/2010
- 2009
  - Nr.4/2009
  - Nr.3/2009
  - Nr.2/2009
  - Nr.1/2009
  - Supplement 1/2009
- 2008
  - Nr.4/2008
  - Nr.3/2008
  - Nr.2/2008
  - Nr.1/2008
  - Supplement 1/2008
- 2007
  - Nr.4/2007
  - Nr.3/2007
  - Nr.2/2007
  - Nr.1/2007
- 2006
  - Nr.4/2006
  - Nr.3/2006
  - Nr.2/2006
  - Nr.1/2006
- 2005
  - Nr.1/2005
Instructions for authors
Online applications
- Send an article
- Online payments
Editorial
About us
Links

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12

Top 10 downloaded articles - April 2024 -

A comprehensive review of Prof...	24
Recomandarea comună EFLM-COLA...	13
Monocyte to high-density lipop...	9
Anti-thyroid peroxidase (TPO) ...	9
Understanding the key differen...	7
Understanding the pathogenesis...	7
Function of the S1P pathway in...	6
Predictive value of expression...	5
The importance of tumor marker...	4
Romanian Review of Laboratory ...	4

Concept, Design & Programming
Dr. Adrian Man

Nr. 31(1)/2023 DOI:10.2478/rrlm-2023-0007

Case report

Management of a case of Castleman's disease coexisting with or occurring after transplanted Hodgkin’s lymphoma

Mihaela Andreescu, Sabina Zurac, Andreea Lacatusu, Andrei T. Tudor, Nicoleta Ilie, Laura G. Tirlea, Rozeta Ionescu, Viola M. Popov, Alina D. Tănase

Correspondence should be addressed to: Mihaela Andreescu

Abstract:

Castleman’s disease is a benign lymphoproliferative disorder. The coexistence of Hodgkin’s lymphoma and multicentric Castleman’s disease is a rare phenomenon. We discuss a case of a 48-year-old female patient who had been in the records of the Colentina Hematology Clinic since 2019, with the diagnosis of classic Hodgkin’s Lymphoma, nodular sclerosis type I BNLI, stage IIXB. For this, she underwent 3 courses of ABVD and 2 courses of BEACOPP, without showing complete remission on PET/CT evaluation at the end of treatment. After that, we initiated rescue therapy and performed 4 IGEV courses, followed by autologous stem cell transplantation. For maintenance treatment, we opted for Brentuximab, but it was discontinued after the first administration due to the appearance of adverse reactions. Subsequently, we decided to perform radiotherapy with 20 fractions cumulating a total dose of 36 Gy. Shortly after the radiotherapy, symptoms reappeared which were suspected to be in the context of a relapse of the disease. For confirmatory diagnosis, we performed a new PET-CT which highlighted metabolically active ganglion images. Further, were carried out lymph node biopsy for histopathological and immunohistochemical examinations were carried out. The underlying disease was diagnosed as plasmacytic subtype, HHV8 negative, multicentric Castleman’s disease. For treatment, we relied on administrations of Siltuximab treatment therapy that showed complete remission. Castleman’s disease presents a unique diagnostic challenge, but a confirmatory diagnosis can be based on a biopsy examination, advisable after each relapse.

Keywords: lymphoid, hyperplasia, lymph node, histopathology, angio-follicular

Received: 13.12.2022
Accepted: 20.1.2023
Published: 24.1.2023

Download full text PDF
(2974 KB)

Andreescu M, Zurac S, Lacatusu A, Tudor AT, Ilie N, Tirlea LG, et al. Management of a case of Castleman's disease coexisting with or occurring after transplanted Hodgkin’s lymphoma. Rev Romana Med Lab. 2023;31(1):59-64. DOI:10.2478/rrlm-2023-0007